Free cash flow remains deeply negative, with the company burning through $930,500 in 2026Q1 alone while struggling to convert earnings into meaningful operating cash flow.
Endovia Health Sciences, Inc. (EDVA) cash flow statement — 13-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|
| Cash from Operations | -5.41M | -4.79M | -8M | -10.19M | -14.09M | -15.13M | -23.1M | -228.41K | 62.39K | -17.6K | 32.11K | 13.07K | 1.22K | -35.65K |
| Operating CF Margin % | - | -6554.54% | -192.62% | -54.05% | -77.92% | -133.73% | -1004.5% | -22.44% | 4.77% | -1.97% | 3.17% | 1.46% | 0.2% | -7.5% |
| Operating CF Growth % | -39.91% | 40.17% | 21.45% | 27.7% | 6.86% | 34.51% | -10015.71% | -466.08% | 454.56% | -154.8% | 145.61% | 975.25% | 103.41% | - |
| Net Income | -17.28M | -24.35M | -23.76M | -21M | -21.71M | -29.05M | -28.67M | -477.23K | 68.21K | -147.53K | -48.85K | 19.15K | -30.09K | -3.24K |
| Depreciation & Amortization | 207.88K | 457.04K | 540.3K | 549.45K | 936.02K | 111.57K | 194.83K | 62.72K | 55.58K | 57.78K | 49.93K | 24.14K | 26.38K | 1.91K |
| Stock-Based Compensation | 1.53M | 8.51M | 2.36M | 1.17M | 0 | 11.13M | 2.33M | 160.79K | 1.66M | 72.19K | 0 | 0 | 0 | 0 |
| Deferred Taxes | 1.15M | 0 | 0 | 0 | 0 | 6.93M | -9.79K | -1.73M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -20.12M | 7.59M | 8.01M | 3.83M | 7.37M | -2.03M | 3.97M | 1.73M | 179.8K | 57.54K | 74.67K | 84.12K | 0 | 0 |
| Working Capital Changes | 280.58K | 3M | 4.85M | 5.26M | -688.65K | -2.22M | -909.93K | 25.32K | -61.39K | 72.16K | 31.02K | -30.22K | 4.92K | -34.32K |
| Change in Receivables | -78.55K | 176.24K | 493.78K | 921.48K | -697.66K | -629.59K | -385.3K | -8.63K | -149.73K | 54.99K | -39.19K | -86.88K | -21.54K | -44.19K |
| Change in Inventory | -575.54K | 285.57K | 1.36M | 1.47M | -1.8M | -1.13M | -220.31K | 11.14K | -16.49K | 22 | -3.64K | -7.28K | -1.77K | -12.54K |
| Change in Payables | -2.15M | 728.69K | 1.16M | 1.06M | 1.59M | 446.15K | -64.36K | -127.17K | 160.61K | 17.14K | 73.86K | 63.94K | 28.23K | 22.41K |
| Cash from Investing | -209.29K | 0 | -3.23K | -14.11K | -102.7K | 0 | -780.25K | -47.94K | -67.57K | -42.23K | -52.08K | -20.59K | -30.39K | 25.77K |
| Capital Expenditures | 11.73K | 0 | -3.23K | -14.11K | -102.7K | 0 | -91.07K | -54.38K | -75.63K | -58.27K | -58.42K | -20.59K | -30.39K | 25.77K |
| CapEx % of Revenue | -3.25% | - | 0.08% | 0.07% | 0.57% | - | 3.96% | 5.34% | 5.78% | 6.51% | 5.77% | 2.29% | 5.02% | 5.42% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | -677.56K | 0 | 8.06K | 16.05K | 6.35K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -221.02K | 0 | 0 | 0 | 0 | 0 | -11.63K | 6.45K | 8.06K | 16.05K | 6.35K | 0 | 0 | 0 |
| Cash from Financing | 5.86M | 5.1M | 7.54M | 6.15M | 14.05M | 18.93M | 22.49M | 292.68K | -5.76K | 16.09K | 74.28K | -10.05K | 53.41K | 28.97K |
| Debt Issued (Net) | 2.26M | 3.8M | 7.54M | 5.57M | 3.41M | -745.3K | 2.36M | -5.17K | -7.76K | -18.91K | -15.72K | -10.05K | -15.69K | -4.95K |
| Equity Issued (Net) | 3.6M | 1.3M | 0 | 0 | 11.43M | 19.63M | 20.18M | 100K | 2K | 35K | 90K | 0 | 69.1K | 33.91K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 9K | 580K | -790.4K | 48.51K | -46.25K | 197.85K | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 225.49K | 266.09K | -364.63K | -4.05M | 250.36K | 3.8M | 388.38K | 16.34K | -10.94K | -43.74K | 54.32K | -17.57K | 24.24K | -6.68K |
| Free Cash Flow | -6.2M | -4.79M | -8.01M | -10.2M | -14.2M | -15.13M | -23.2M | -282.79K | -13.24K | -75.87K | -26.31K | -7.51K | -29.17K | -9.88K |
| FCF Margin % | 1717.18% | -6554.54% | -192.7% | -54.13% | -78.49% | -133.73% | -1008.46% | -27.78% | -1.01% | -8.47% | -2.6% | -0.84% | -4.81% | -2.08% |
| FCF Growth % | -9.26% | 40.19% | 21.52% | 28.13% | 6.18% | 34.76% | -8102.5% | -2035.71% | 82.55% | -188.37% | -250.35% | 74.26% | -195.22% | - |
| FCF per Share | -2.02 | -8.79 | -23.93 | -38.46 | -60.75 | -83.78 | -600.59 | -11.49 | -0.56 | -3.23 | -1.12 | -0.00 | -0.01 | -0.00 |
| FCF Conversion (FCF/Net Income) | 0.36x | 0.19x | 0.34x | 0.49x | 0.65x | 0.52x | 0.81x | 0.04x | 0.91x | 0.12x | -0.66x | 0.68x | -0.04x | 11.00x |
| Interest Paid | 71.16K | 0 | 795.02K | 0 | 204.59K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying EDVA stock.
Endovia Health Sciences, Inc. (EDVA) generated $-4.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Endovia Health Sciences, Inc. (EDVA) reported negative free cash flow of $4.8M in 2025, indicating capital requirements exceeded cash from operations.
Endovia Health Sciences, Inc. (EDVA) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Imminent Liquidity Crisis
Metrics are mathematically derived from official filings.
Persistent Disconnect Between Earnings Reality
As reported in quarterly filings, SBEV consistently exhibits a wide gap between net income and operating cash flow, with the most recent data showing an OCF/NI ratio that suggests reported losses are not fully capturing the underlying cash burn required to sustain the company's current operational footprint.
The persistent divergence between net income and operating cash flow indicates that non-cash charges and accruals are significantly distorting the company's true financial health. Investors should monitor this relationship closely, as the inability to align accounting profits with cash generation suggests that the business model remains fundamentally unviable.
Free Cash Flow Remains Deeply Negative
Based on the provided cash flow statements, SBEV's free cash flow trajectory is consistently negative, with the company burning through cash in nearly every period, which underscores the structural inability of the current beverage portfolio to generate sufficient internal funding to cover its ongoing operating and capital requirements.
The consistent negative free cash flow trend highlights a reliance on external financing that appears increasingly unsustainable given the company's current liquidity position. This trajectory suggests that without a radical shift in sales velocity or cost management, the company will continue to deplete its remaining cash reserves.
Working Capital Volatility Masks Instability
According to historical cash flow data, SBEV's working capital changes have been highly erratic, with significant swings in accounts receivable and payables that suggest a lack of disciplined cash management and potential difficulties in collecting payments from distributors or managing inventory levels effectively across its niche brands.
The volatility in working capital adjustments may indicate that the company is struggling to manage its supply chain and retail relationships, leading to unpredictable cash inflows. This instability warrants further investigation into whether the company is forced to offer extended payment terms to maintain its limited retail shelf presence.
SBC Distorts True Cash Burn
As evidenced by the quarterly cash flow statements, stock-based compensation frequently acts as a significant non-cash adjustment, which obscures the true magnitude of the company's cash burn by artificially inflating the reported cash flow metrics relative to the actual capital required to maintain operations.
The reliance on stock-based compensation as a primary tool for managing cash flow suggests that the company is attempting to preserve its limited liquidity at the expense of shareholder dilution. Analysts should be wary of these adjustments, as they do not represent a sustainable path toward achieving positive free cash flow.